Teva says the completion of its restructuring plan has put the firm in a position to increase its turnover through sales of newly-launched products – including biosimilars, brands and new generic launches – as well as to improve its profit margins through continued optimization of its manufacturing operations.
The Israeli company saw its overall sales drop by 8% to $16.887bn in 2019 – translating to a 5% constant-currency...